[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, eteplirsen has been approved by the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping. Clinical trials have shown that eteplirsen can increase dystrophin levels and improve ambulation and pulmonary function in DMD patients. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]